Hoth Therapeutics
One Rockefeller Plaza
Suite 1039
New York
New York
10020
United States
Website: https://www.hoththerapeutics.com/
About Hoth Therapeutics
Hoth Therapeutics Inc. is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis.LEADERSHIP:
CEO: Robb Knie
208 articles about Hoth Therapeutics
-
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
3/27/2024
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment.
-
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
3/27/2024
Hoth Therapeutics, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share.
-
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
3/19/2024
Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic.
-
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
2/29/2024
Hoth Therapeutics, Inc. today announced that it will continue its work with Venable, LLP to develop and protect its intellectual property.
-
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
2/26/2024
Hoth Therapeutics, Inc. announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
-
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
2/13/2024
Hoth Therapeutics, Inc. today announced that Robb Knie , Chief Executive Officer, is scheduled to attend the BIO CEO and Investor Conference in New York, NY.
-
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
1/18/2024
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001, which is being developed as a potential treatment for cancer patients undergoing treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI).
-
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
12/27/2023
Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.
-
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
12/5/2023
Hoth Therapeutics, Inc. today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP).
-
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
11/14/2023
Hoth Therapeutics, Inc. today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic.
-
Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023
11/10/2023
Hoth Therapeutics, Inc. is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL.
-
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
10/5/2023
Hoth Therapeutics, Inc. today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.
-
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
10/2/2023
Hoth Therapeutics, Inc. today announced the Pre-IND meeting requested on September 8th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023.
-
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
9/15/2023
Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,100,000 shares of its common stock at a purchase price of $2.63 per share of common stock.
-
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
9/13/2023
Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.
-
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
9/13/2023
Hoth Therapeutics, Inc. today announced that HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM) achieved positive preclinical results in a study sponsored by Hoth.
-
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients
9/11/2023
Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM).
-
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
9/6/2023
Hoth Therapeutics, Inc. today announced that it has completed its analysis of the data from its Phase 1b clinical trial of BioLexa as a therapeutic for atopic dermatitis.
-
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
8/9/2023
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer's Disease ("AD"), achieved positive preclinical end points in a study conducted at Washington University, St. Louis.
-
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
7/25/2023
Hoth Therapeutics, Inc. today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).